We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

IRBM’s Advent Manufactures 13,000 Doses of COVID-19 Vaccine for Use in Phase 2/3 Clinical Trials

Product News   May 28, 2020

 
IRBM’s Advent Manufactures 13,000 Doses of COVID-19 Vaccine for Use in Phase 2/3 Clinical Trials

Credit: Pixabay

FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

Sinovac COVID-19 Vaccine Collaboration Receives Approval for Phase III Trial

Product News

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced an update to its previously announced partnership with Butantan, a leading Brazilian producer of immunobiologic products and vaccines.

READ MORE

Cobra Biologics Delivers Final Plasmids for Production of CG01 in CombiGene's Epilepsy Project

Product News

The milestone in the project paves the way for production of novel gene therapy drug candidate designed to treat drug-resistant focal epilepsy.

READ MORE

Byondis’ Investigational Antibody-Drug Conjugate Selected for Trial in Early-Stage Breast Cancer

Product News

Byondis has announced that Quantum Leap selected the company’s investigational antibody-drug conjugate SYD985 for a new investigational treatment arm in its ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer.

READ MORE

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE